89bio Inc. (ETNB) Announces Proposed 3M Common Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St set for higher open after retail earnings; Moderna soars
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
89bio Inc. (ETNB) PT Raised to $58 at BTIG
September 14, 2020 5:04 PM EDTBTIG analyst Julian Harrison raised the price target on 89bio Inc. (NASDAQ: ETNB) to $58.00 (from $51.00) while maintaining a Buy rating.... More
89bio Inc. (ETNB) Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
September 14, 2020 7:05 AM EDT89bio, Inc. (Nasdaq: ETNB) today announced positive topline results from its Phase 1b/2a trial with BIO89-100, an investigational FGF21 analog, in patients with nonalcoholic steatohepatitis (NASH). All dose groups demonstrated significant reductions in liver fat at week 13, with relative reductions up to 60% versus baseline and up to 70% versus placebo, as measured by magnetic resonance imaging... More
